Form 4: Sarepta Therapeutics Director Claude Nicaise Reports Acquisition of Stock and Stock Options

Director Claude Nicaise reports acquisition of Sarepta Therapeutics stock and stock options.

Summary

• On March 10, 2025, Claude Nicaise, a director of Sarepta Therapeutics, Inc., reported the acquisition of 2,383 shares of common stock and 4,792 stock options.
• The common stock was acquired through restricted stock units (RSUs) which vest on March 10, 2026.
• The stock options, with an exercise price of $99.69, become exercisable on March 10, 2026, and expire on March 10, 2035.
• Following these transactions, Nicaise directly owns 20,557 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing insider transactions.

Positives

• A director's acquisition of company stock and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates